4.7 Article

Redox Regulation via Glutaredoxin-1 and Protein S-Glutathionylation

Journal

ANTIOXIDANTS & REDOX SIGNALING
Volume 32, Issue 10, Pages 677-700

Publisher

MARY ANN LIEBERT, INC
DOI: 10.1089/ars.2019.7963

Keywords

fatty liver disease; NAFLD; NASH; hindlimb ischemia; peripheral artery disease

Funding

  1. National Institute of Health [R01 DK103750, R01 HL133013, R21 AG058983, R21 AA026922, R01 HL137771, R03 AG 051857]
  2. American Heart Association [16GRNT27660006]
  3. European Cooperation in Science and Technology (COST Action) [BM1203/EU-ROS]
  4. Metabolic Clinical Research Collaborative
  5. NIH/Boston University Clinical & Translational Science Institute [1UL1TR001430]
  6. Evans Junior Faculty Research Award by the Department of Medicine of Boston University
  7. NIH through the Whitaker Cardiovascular Institute at Boston University [T32 HL007224]

Ask authors/readers for more resources

Critical Issues: Glutaredoxins mainly catalyze the removal of protein-bound GSH and help maintain protein thiols in a highly reduced state without exerting direct antioxidant properties. Conversely, glutathione S-transferase (GST), peroxiredoxins, and occasionally glutaredoxins can also catalyze protein S-glutathionylation, thus promoting a dynamic redox environment. Recent Advances: The latest studies of glutaredoxin-1 (Glrx) transgenic or knockout mice demonstrate important distinct roles of Glrx in a variety of pathologies. Endogenous Glrx is essential to maintain normal hepatic lipid homeostasis and prevent fatty liver disease. Further, in vivo deletion of Glrx protects lungs from inflammation and bacterial pneumonia-induced damage, attenuates angiotensin II-induced cardiovascular hypertrophy, and improves ischemic limb vascularization. Meanwhile, exogenous Glrx administration can reverse pathological lung fibrosis. Future Directions: Although S-glutathionylation modifies many proteins, these studies suggest that S-glutathionylation and Glrx regulate specific pathways in vivo, and they implicate Glrx as a potential novel therapeutic target to treat diverse disease conditions.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available